

Erratum to current state of immunotherapy for non-small cell lung cancer

Jyoti Malhotra, Salma K. Jabbour, Joseph Aisner

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

Correspondence to: Jyoti Malhotra, MD, MPH. Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 08903, USA. Email: jm1940@cinj.rutgers.edu.

doi: 10.21037/tlcr.2017.08.08

View this article at: <http://dx.doi.org/10.21037/tlcr.2017.08.08>

Erratum to: *Transl Lung Cancer Res* 2017;6:196-211

In the April 2017 issue of *Translational Lung Cancer Research (TLCR)*, the review article “*Current state of immunotherapy for non-small cell lung cancer*” (1) was published with some errors. Borghaei *et al.* is labeled as CheckMate 17 instead of CheckMate 057 and conversely, Brahmer *et al.* is labeled as CheckMate 057 instead of CheckMate 017. Also in *Tables 2* and *3*, these two trials have been labeled in reverse.

Also, the correct reference for CheckMate 021 (nivolumab in combination with chemotherapy arm) is reference number 23. The correct reference for CheckMate 021 (nivolumab and ipilimumab arm) is: Hellmann MD, Rizvi NA, Goldman JW, *et al.* Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. *Lancet Oncol* 2017;18:31-41.

We are sorry for the inconvenience caused.

References

1. Malhotra J, Jabbour SK, Aisner J. Current state of immunotherapy for non-small cell lung cancer. *Transl Lung Cancer Res* 2017;6:196-211.

Cite this article as: Malhotra J, Jabbour SK, Aisner J. Erratum to current state of immunotherapy for non-small cell lung cancer. *Transl Lung Cancer Res* 2017;6(5):612. doi: 10.21037/tlcr.2017.08.08